PRINCETON, N.J.--(BUSINESS WIRE)-- UroGen Pharma Ltd. (URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today ...

PRINCETON, N.J., Oct. 02, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company focused on developing and commercializing innovative solutions for urothelial and specialty ...

For individuals facing fear, uncertainty and repeated procedures associated with recurrent low-grade intermediate-risk bladder tumors, timely access to treatment can be critical. ZUSDURI, the first ...

UGN-102 showed high complete response rates in both ENVISION and ATLAS trials for low-grade, intermediate-risk NMIBC. Dysuria was the most common side effect of UGN-102, with other side effects ...

NAPOLI 3, a phase 3 study of NALIRIFOX in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): Final overall survival (OS) analysis and characteristics of the long-term survivors.

ZUSDURI shows promising long-term efficacy in treating low-grade intermediate-risk bladder cancer, maintaining event-free survival in patients. UroGen Pharma Ltd. announced findings published in the ...

UroGen Pharma Ltd. (NASDAQ:URGN) on Sunday highlighted a duration of response of nearly four years from a long-term follow-up study with Jelmyto (mitomycin) for pyelocalyceal solution. The U.S. Food ...

Urogen Pharma Ltd. overcame a decidedly mixed U.S. FDA advisory panel meeting to nail down approval of Zusduri (mitomycin, formerly known as UGN-102) for recurrent low-grade, intermediate-risk, ...

HC Wainwright & Co. analyst Raghuram Selvaraju downgraded the rating on UroGen Pharma Ltd. (NASDAQ:URGN) from Buy to Neutral. Selvaraju points out that the FDA’s Oncologic Drugs Advisory Committee ...

The benefit-risk profile was favorable, supporting UGN-102 mitomycin gel as a nonsurgical alternative to TURBT in patients with recurrent low-grade, intermediate-risk non-muscle invasive bladder ...